What is Collaborations Pharmaceuticals?
Collaborations Pharmaceuticals, Inc. (CPI) is a research and development entity focused on novel therapeutics for rare and neglected diseases. Beyond its preclinical pipeline, CPI has developed proprietary software solutions, including Assay Central® for data curation and machine learning, MegaTox®, MegaTrans®, and MegaPredict® for curated model bundles, and generative software such as MegaSyn and UV-adVISor for predicting UV-Vis spectra. Operating from laboratories within the NC State Incubator, CPI leverages extensive experience in preclinical and computational drug discovery and toxicity prediction.
How much funding has Collaborations Pharmaceuticals raised?
Collaborations Pharmaceuticals has raised a total of $104K across 1 funding round:
Debt
$104K
Debt (2021): $104K with participation from PPP
Key Investors in Collaborations Pharmaceuticals
PPP
Public-Private Partnership
What's next for Collaborations Pharmaceuticals?
The company's recent large-scale, late-stage funding indicates a transition towards scaling operations and potentially advancing its therapeutic candidates through later stages of clinical development. This strategic investment is likely to accelerate the commercialization of its rare disease treatments and further enhance its computational drug discovery platforms, positioning CPI for significant growth in the biopharmaceutical and computational chemistry sectors.
See full Collaborations Pharmaceuticals company page
